Compliance Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018
NATCOPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Natco Pharma submitted a routine compliance certificate to BSE and NSE under Regulation 74(5) of SEBI's Depositories and Participants Regulations. The certificate, issued by the company's Registrar and Share Transfer Agent (Venture Capital and Corporate Investments Pvt Ltd), confirms that shares received for dematerialization during the quarter ended March 31, 2025 were properly mutilated, cancelled, and updated in the company's records as registered with NSDL and CDSL within the required 15-day timeline. The details of these securities have also been furnished to the stock exchanges. This is a standard quarterly procedural filing with no new financial or business information.
This is a routine regulatory compliance filing with no material impact on shareholders or the stock price. It simply confirms the RTA is processing share dematerialization requests correctly as required by SEBI.